Search research articles
Contact Us
Filters
Showing results (861-870 of 1,038) with videos related to
Page
of 104
Sort By:
American Journal of Physiology. Heart and Circulatory Physiology
|
June 7, 2024
<i>Runx1</i> is sufficient but not required for cardiomyocyte cell-cycle activation
Kaelin A Akins, Michael A Flinn, Samantha K Swift, et al.
BMC Genomics
|
May 29, 2019
A new reference genome for Sorghum bicolor reveals high levels of sequence similarity between sweet and grain genotypes: implications for the genetics of sugar metabolism
Elizabeth A Cooper, Zachary W Brenton, Barry S Flinn, et al.
Blood
|
March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.
Cancer Medicine
|
May 28, 2025
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators
Tara Graff, Ian Flinn, Jeff P Sharman, et al.
Blood Advances
|
September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Joseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
John M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C Byrd, Richard R Furman, Steven E Coutre, et al.
The New England Journal of Medicine
|
August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
Laura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
American Journal of Hematology
|
August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
Susan O'Brien, Manish Patel, Brad S Kahl, et al.
Seminars in Oncology
|
February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
Leo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Page
of 104
Search research articles
Search
Showing results (861-870 of 1,038) with videos related to
Sort By:
Page
of 104
American Journal of Physiology. Heart and Circulatory Physiology
|
June 7, 2024
<i>Runx1</i> is sufficient but not required for cardiomyocyte cell-cycle activation
Kaelin A Akins, Michael A Flinn, Samantha K Swift, et al.
BMC Genomics
|
May 29, 2019
A new reference genome for Sorghum bicolor reveals high levels of sequence similarity between sweet and grain genotypes: implications for the genetics of sugar metabolism
Elizabeth A Cooper, Zachary W Brenton, Barry S Flinn, et al.
Blood
|
March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.
Cancer Medicine
|
May 28, 2025
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators
Tara Graff, Ian Flinn, Jeff P Sharman, et al.
Blood Advances
|
September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Joseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
John M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C Byrd, Richard R Furman, Steven E Coutre, et al.
The New England Journal of Medicine
|
August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
Laura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
American Journal of Hematology
|
August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
Susan O'Brien, Manish Patel, Brad S Kahl, et al.
Seminars in Oncology
|
February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
Leo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Page
of 104